FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090192471> ?p ?o ?g. }

• W2090192471 endingPage "334" @default.
• W2090192471 startingPage "312" @default.
• W2090192471 abstract "HistopathologyVolume 45, Issue 4 p. 312-334 Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours? H Grabsch, H Grabsch Academic Unit of Pathology, School of Medicine, University of Leeds, Leeds, and Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, Oxford, UKSearch for more papers by this authorD Kerr, D Kerr Academic Unit of Pathology, School of Medicine, University of Leeds, Leeds, and Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, Oxford, UKSearch for more papers by this authorP Quirke, P Quirke Academic Unit of Pathology, School of Medicine, University of Leeds, Leeds, and Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, Oxford, UKSearch for more papers by this author H Grabsch, H Grabsch Academic Unit of Pathology, School of Medicine, University of Leeds, Leeds, and Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, Oxford, UKSearch for more papers by this authorD Kerr, D Kerr Academic Unit of Pathology, School of Medicine, University of Leeds, Leeds, and Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, Oxford, UKSearch for more papers by this authorP Quirke, P Quirke Academic Unit of Pathology, School of Medicine, University of Leeds, Leeds, and Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, Oxford, UKSearch for more papers by this author First published: 06 October 2004 https://doi.org/10.1111/j.1365-2559.2004.01901.xCitations: 12 Heike Grabsch MD, Academic Unit of Pathology, School of Medicine, University of Leeds, Algernon Firth Building, Leeds LS2 9JT, UK. e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Mellin W. Cytophotometry in tumor pathology. A critical review of methods and applications, and some results of DNA analysis. Pathol. Res. Pract. 1990; 186; 37–62. 2 Rew DA. Significance of aneuploidy. Br. J. Surg. 1994; 81; 1416–1422. 3 Friedlaender ML, Hedley DW, Taylor IW. Clinical and biological significance of aneuploidy in human tumours. J. Clin. Pathol. 1984; 37; 961–974. 4 Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer 1990; 65; 1194–1205. 5 Sasaki K, Murakami T. Clinical application of flow cytometry for DNA analysis of solid tumours. Acta Pathol. Jpn 1992; 42; 1–14. 6 Ross J. DNA ploidy and cell cycle analysis in pathology. New York: Igaku-shoin Medical Publisher Inc., 1996. 7 Dressler L, Bartow SA. DNA flow cytometry in solid tumours: practical aspects and clinical applications. Semin. Diagn. Pathol. 1989; 6; 55–82. 8 Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC Cancer Base no. 5. Lyon: IARC Press, 2001. 9 Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001; 37; S4–S66. 10 Yu JM, Yang LH, Guo-Qian Cehn YT et al. Flow cytometric analysis DNA content in esophageal carcinoma. Correlation with histologic and clinical features. Cancer 1989; 64; 80–82. 11 Ruol A, Segalin A, Panozzo M et al. Flow cytometric DNA analysis of squamous cell carcinoma of the esophagus. Cancer 1990; 65; 1185–1188. 12 Doki Y, Shiozaki H, Tahara H et al. Prognostic value of DNA ploidy in squamous cell carcinoma of esophagus. Analyzed with improved flow cytometric measurement. Cancer 1993; 72; 1813–1818. 13 Ikeda G, Isaji S, Das BC, Watanabe M, Kawarada Y. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer 1999; 86; 1396–1405. 14 Edwards JM, Jones DJ, Wilkes SJ, Hillier VF, Hasleton PS. Ploidy as a prognostic indicator in oesophageal squamous carcinoma and its relationship to various histological criteria. J. Pathol. 1989; 159; 35–41. 15 Mannell A, Hunter SJ. DNA ploidy in oesophageal cancer. A preliminary report. S. Afr. J. Surg. 1990; 28; 55–58. 16 Robey-Cafferty SS, El-Naggar AK, Sahin AA, Bruner JM, Ro JY, Cleary KR. Prognostic factors in esophageal squamous carcinoma. A study of histologic features, blood group expression, and DNA ploidy. Am. J. Clin. Pathol. 1991; 95; 844–849. 17 Lam KY, Ma L, Law SY, Cheung LK, Luk TF, Wong J. Use of flow cytometry in the analysis of stage III squamous cell carcinoma of the oesophagus and its association with MIB-1. J. Clin. Pathol. 1996; 49; 975–978. 18 Yasunaga M, Tabira Y, Imaoka S, Kitamura N. Prognostic value of mitotic metaphase rate in oesophageal cancer. Eur. J. Surg. 2000; 166; 616–621. 19 Watanabe M, Kuwano H, Tanaka S, Toh Y, Sadanaga N, Sugimachi K. Flow cytometric DNA Analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus. Cancer 1999; 85; 2322–2328. 20 Stephens JK, Bibbo M, Dytch H, Maiorana A, Ruol A, Little AG. Correlation between automated karyometric measurements of squamous cell carcinoma of the esophagus and histopathologic and clinical features. Cancer 1989; 64; 83–87. 21 Matsuura A, Sugimachi K, Ueo H, Kuwano H, Koga Y, Okamura T. Malignant potentiality of squamous cell carcinoma of the esophagus predictable by DNA analysis. Cancer 1986; 57; 1810–1814. 22 Kaketani K, Saito T, Kobayashi M. Flow cytometric analysis of nuclear DNA content in esophageal cancer. Aneuploidy as an index for highly malignant potential. Cancer 1989; 64; 887–991. 23 Minu AR, Endo M, Sunagawa M. Role of DNA ploidy patterns in esophageal squamous cell carcinoma. An ultraviolet microspectrophotometric study. Cancer 1994; 74; 578–585. 24 Wang LS, Chow KC, Chi KH et al. Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors. Am. J. Gastroenterol. 1999; 94; 1933–1940. 25 Blant SA, Ballini JP, Caron CTL, Fontolliet C, Monnier P, Laurini NR. Evolution of DNA ploidy during squamous cell carcinogenesis in the esophagus. Dis. Esophag. 2001; 14; 178–184. 26 Matsuura H, Kuwamo H, Morita M et al. Predicting recurrence time of esophageal carcinoma through assessment of histologic factors and ploidy. Cancer 1991; 67; 1406–1411. 27 Walsh TN, Dorman T, Droogan O et al. DNA ploidy in squamous oesophageal carcinoma. Surg. Oncol. 1992; 1; 37–42. 28 Ikebe M, Kitamura K, Baba K, Morita M, Tsutsui S, Sugimachi K. DNA ploidy as a prognostic factor in early esophageal carcinoma. Hepatogastroenterology 1993; 40; 232–235. 29 Chanvitan A, Nekarda H, Casson AG. Prognostic value of DNA index, S-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous cell carcinomas in Thailand. Int. J. Cancer 1995; 63; 381–386. 30 Kuwano H, Sumiyoshi K, Nozoe T, Yasuda M, Watanabe M, Sugimachi K. The prognostic significance of the cytophotometric DNA content and its relationship with the argyrophilic nucleolar organizer regions (AgNor) and proliferating cell nuclear antigen (PCNA) in oesophageal cancer. Eur. J. Surg. Oncol. 1995; 21; 368–373. 31 Sugimachi K, Matsuoka H, Ohno S, Mori M, Kuwano H. Multivariate approach for assessing the prognosis of clinical oesophageal carcinoma. Br. J. Surg. 1988; 75; 1115–1118. 32 Bottger T, Storkel S, Stockle M et al. DNA image cytometry. A prognostic tool in squamous cell carcinoma of the esophagus? Cancer 1991; 67; 2290–2294. 33 Bottger T, Storkel S, Stockle M et al. Image analysis of DNA cytometry for assessing prognosis after resection of esophageal cancer. Chirurg. 1991; 62; 467–472. 34 Pujol i Gebelli J. Clinical and biological significance of DNA content in human squamous carcinoma of the esophagus. Diss. Abstract Int. 1992; 53; 705. 35 Patil P, Redkar A, Patel SG et al. Prognosis of operable squamous cell carcinoma of the esophagus. Relationship with clinicopathological features and DNA ploidy. Cancer 1993; 72; 20–24. 36 Seitz JF, Perrier H, Monges G, Giovanni M, Gouvernet J. Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53. Gastroenterol. Clin. Biol. 1995; 19; 465–474. 37 Kaketani K, Saito T, Kuwahara A et al. DNA stem line heterogeneity in esophageal cancer accurately identified by flow cytometric analysis. Cancer 1993; 72; 3564–3570. 38 Sasaki K, Murakami T, Murakami T, Nakamura M. Intratumoral heterogeneity in DNA ploidy of esophageal squamous cell carcinomas. Cancer 1991; 68; 2403–2406. 39 Tsutsui S, Kuwano H, Mori M, Matsuura H, Sugimachi K. Comparison of cell nuclear DNA contents between intraepithelial and invasive components of oesophageal squamous cell carcinoma. Eur. J. Cancer 1991; 27; 620–624. 40 Tsutsui S, Kuwano H, Mori M, Matsuura H, Sugimachi K. Flow cytometric analysis of DNA content in primary and metastatic lesions of esophageal squamous cell carcinoma. Cancer 1992; 70; 2586–2591. 41 Haraguchi Y, Baba M, Takao S, Yoshinaka H, Hase S, Aikou T. Flow cytometric analysis of DNA heterogeneity in superficial carcinoma of the esophagus. Cancer 1995; 75; 914–919. 42 Antonioli DA. Esophagus, 3rd edn. Oxford: Oxford University Press, 2001; 123–146. 43 Chanvitan A, Puttawibul P, Casson AG. Flow cytometry in squamous cell esophageal cancer and precancerous lesions. Dis. Esophag. 1997; 10; 206–210. 44 Zuo L, Ling P, Qi F et al. Flow cytometric DNA analyses of epithelial dysplasia of the esophagus. Anal. Quant. Cytol. Histol. 2000; 22; 175–177. 45 Herlin P, Duigou F, Masson E et al. DNA cytometric abnormalities in human esophageal squamous intraepithelial and invasive carcinomas. Anal. Quant. Cytol. Histol. 1995; 17; 8–14. 46 Itakura Y, Sasano H, Mori S, Nagura H. DNA ploidy in human esophageal squamous dysplasias and squamous cell carcinomas as determined by image analysis. Mod. Pathol. 1994; 7; 867–873. 47 Rubio CA, Liu FS, Zhao HZ. Histological classification of intraepithelial neoplasias and microinvasive squamous carcinoma of the esophagus. Am. J. Surg. Pathol. 1989; 13; 685–690. 48 Montgomery EA, Hartmann DP, Carr NJ, Holterman DA, Sobin LH, Azumi N. Barrett esophagus with dysplasia. Flow cytometric DNA analysis or routine, paraffin-embedded mucosal biopsies. Am. J. Clin. Pathol. 1996; 106; 298–304. 49 Segalin A, Ruol A, Panozzo M, Bonavina L, Bianchi LC, Peracchia A. Flow cytometric DNA analysis does not predict the radiochemoresponsiveness of esophageal cancer. J. Surg. Oncol. 1993; 54; 87–90. 50 Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, LantZ. PE, Listrom MB. Gastrointestinal pathology. An atlas and text, 2nd edn. Philadelphia, New York: Lippincott-Raven, 1999. 51 Bas PL, Wijnhoven MD, Tilanus HW, Dinjens WNM. Molecular biology of Barrett's adenocarcinoma. Ann. Surg. 2001; 233; 322–337. 52 Sarbia M, Molsberger G, Willers R et al. The prognostic significance of DNA ploidy in adenocarcinomas of the esophagogastric junction. J. Cancer Res. Clin. Oncol. 1996; 122; 186–188. 53 Schneeberger AL, Finley RJ, Troster M, Lohmann R, Keeney M, Inculet RI. The prognostic significance of tumor ploidy and pathology in adenocarcinoma of the esophagogastric junction. Cancer 1990; 65; 1206–1210. 54 Flejou JF, Doublet B, Potet F, Metayer J, Hemet J. DNA ploidy in adenocarcinoma of Barrett's esophagus. Ann. Pathol. 1990; 10; 161–165. 55 Reid B, Haggitt R, Rubin C, Rabinovitch P. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987; 93; 1–11. 56 Reid B, Sanchez C, Blount P, Levine D. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105; 119–129. 57 Nakamura T, Nekarda H, Hoelscher AH et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994; 73; 1785–1794. 58 Khan M, Bui HX, Del Rosario A et al. Role of DNA content determination by image analysis in confirmation of dysplasia in Barrett's esophagus. Mod. Pathol. 1994; 7; 169–174. 59 Menke-Pluymers MB, Mulder AH, Hop WC, Van Blankenstein M, Tilanus HW. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 1994; 35; 1348–1351. 60 Menke-Pluymers MB, Hop WC, Mulder AH, Tilanus HW. DNA ploidy as a prognostic factor for patients with an adenocarcinoma in Barrett's esophagus. Hepatogastroenterology 1995; 42; 786–788. 61 Bottger T, Dutkowski P, Kirkpatrick CJ, Junginger T. Prognostic significance of tumor ploidy and histomorphological parameter in adenocarcinoma of Barrett's esophagus. Dig. Surg. 1999; 16; 180–185. 62 Adler RH. The lower oesophagus lined by columnar epithelium: its association with hiatal hernia, ulcer, stricture and tumor. J. Thorac. Cardiovasc. Surg. 1963; 45; 13–34. 63 Buttar NS, Wang KK, Sebo TJ et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120; 1630–1639. 64 Reid BJ, Haggitt RC, Rubin CE et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 1988; 19; 166–178. 65 Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 1998, 93; 1028–1032. 66 Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 2002; 97; 1888–1895. 67 Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br. J. Surg. 1988; 75; 760–763. 68 Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32; 1441–1446. 69 Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus. Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 2000; 95; 1667–1676. 70 Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am. J. Gastroenterol. 1999; 94; 3413–3419. 71 Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120; 1607–1619. 72 O'Connor J, Falk G, Richter J. The incidence of adenocarcinoma and dysplasia in Barrett's oesophagus with high grade dysplasia. Am. J. Gastroenterol. 1999; 94; 2037–2042. 73 Montgomery E, Bronner M, Goldblum J et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 2001; 32; 368–378. 74 Haggitt RC, Reid BJ, Rabinovitch PS, Rubin CE. Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am. J. Pathol. 1988; 131; 53–61. 75 Levine D, Reid B, Haggitt R, Rubin C, Rabinovitch P. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium. Gastroenterology 1989; 96; 355–367. 76 Gimenez A, Minguela A, Haro L et al. DNA ploidy status and proliferative activity as markers of malignant potential in Barretts esophagus: flow cytometric study using routinely paraffin-embedded tissue. World J. Surg. 2000; 24; 72–77. 77 Spiethoff A, Jakobs R, Martin W-R, Riemann JF, Bohrer MH. DNA-zytometrische Untersuchungen der Barrett-Mukosa. Med. Klin. 2001; 96; 208–211. 78 Fennerty M, Sampliner R, Way D, Riddell R, Steinbronn K, Garewal H. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989; 97; 815–820. 79 Sciallero S, Giaretti W, Bonelli L et al. DNA content analysis of Barrett's esophagus by flow cytometry. Endoscopy 1993; 29; 648–651. 80 Teodori L, Goehde W, Persiani M et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998; 34; 257–263. 81 James PD, Atkinson M. Value of DNA image cytometry in the prediction of malignant change in Barrett's oesophagus. Gut 1989; 30; 899–905. 82 Reid B, Blount P, Rubin C, Levine D, Haggitt R, Rabinovitch P. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102; 1212–1219. 83 Lauren P. The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 1965; 64; 31–49. 84 Teodori L, Capurso L, Cordelli E et al. Cytometrically determined relative DNA content as an indicator of neoplasia in gastric lesions. Cytometry 1984; 5; 63–70. 85 Weiss H, Gutz HJ, Schroter J, Wildner GP. DNA distribution pattern in chronic gastritis. I. DNA ploidy and cell cycle distribution. Scand. J. Gastroenterol. 1989; 24; 643–648. 86 Odegaard S, Hostmark J, Skagen DW, Schrumpf E, Laerum OD. Flow cytometric DNA studies in normal human gastric mucosa, gastritis and resected stomachs. Scand. J Gastroenterol. 1987; 22; 750–756. 87 Zuo LF. DNA ploidy in gastric precancerous lesions. Chin. J. Oncol. 1991; 13; 180–183. 88 Ming SC. Malignant potential of gastric epithelial polyps. In SC Ming, ed. Precursors of gastric cancer. New York: Praeger Publisher, 1984; 219–230. 89 Petrova AS, Subrichina GN, Tschistjakova OV et al. Flow cytometry, cytomorphology, histology and autoradiography in human gastric hyperplastic polyps and the surrounding mucosa. Oncology 1982; 39; 308–313. 90 Ming S-C. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1998; 1; 31–50. 91 Macartney JC, Camplejohn RS. DNA flow cytometry of histological material from dysplastic lesions of human gastric mucosa. J. Pathol. 1986; 150; 113–118. 92 Boecking A, Biesterfeld S, Liu S. DNA distribution in gastric cancer and dysplasia. In YC Zhang, K Kawai eds. Precancerous conditions and lesions of the stomach. Berlin, Heidelberg: Springer-Verlag, 1993; 103–120. 93 Sasaki H, Hashimoto T, Kawachino K, Takahashi M. Intratumoral regional differences in DNA ploidy of gastrointestinal carcinomas. Cancer 1988; 62; 2569–2575. 94 Haraguchi M, Okamura T, Korenaga D, Tsujitani S, Marin P, Sugimachi K. Heterogeneity of DNA ploidy in patients with undifferentiated carcinomas of the stomach. Cancer 1987; 59; 922–924. 95 Saito A, Korenaga D, Haraguchi M, Maehara Y, Sugimachi K. Heterogeneity in gastric carcinoma with special reference to DNA content and mitotic activity: histopathologic differentiation. J. Surg. Oncol. 1992; 51; 14–18. 96 Yonemura Y, Matsumoto H, Nimomiya I et al. Heterogeneity of DNA ploidy in gastric cancer. Anal. Cell Pathol. 1992; 4; 61–67. 97 Osterheld MC, Laurini R, Saraga E, Bosman FT. Evaluation of heterogeneity in early gastric cancer. Anal. Cell Pathol. 1999, 19; 67–72. 98 Imada T, Yamamoto Y, Fukuzawa K et al. Flow cytometric analysis of nuclear DNA heterogeneity in gastric cancer. Jpn J. Clin. Oncol. 1997; 27; 221–226. 99 Furuya T, Uchiyama T, Murakami T et al. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin. Cancer Res. 2000; 6; 2815–2820. 100 Danova M, Riccardi A, Mazzini G et al. Flow cytometric analysis of paraffin-embedded material in human gastric cancer. Anal. Quant. Cytol. Histol. 1988; 10; 200–206. 101 Wyatt JI, Quirke P, Ward DC et al. Comparison of histopathological and flow cytometric parameters in prediction of prognosis in gastric cancer. J. Pathol. 1989; 158; 195–201. 102 Baba H, Korenaga D, Okamura T, Saito A, Watanabe A, Sugimachi K. Prognostic significance of DNA content with special reference to age in gastric cancer. Cancer 1989; 63; 1768–1772. 103 Baretton G, Carstensen O, Schardey M, Lohrs U. DNA-ploidy and survival in gastric carcinomas: a flow-cytometric study. Virchows Arch. A 1991; 418; 301–309. 104 Tsushima K, Nagorney DM, Cha SS, Reiman HM. Correlation of DNA ploidy, histopathology, stage and clinical outcome in gastric carcinoma. Surg. Oncol. 1992; 1; 17–25. 105 Suh KS, Min SK. Flow cytometric DNA analysis of gastric cancer—correlation with histology and clinical outcome. J. Korean Med. Sci. 1993; 8; 348–354. 106 Carlini M, Garofalo A, Rinaldi G et al. Gastric cancer cell DNA content correlates with early and late results after gastrectomy. Int. Surg. 1994; 79; 114–119. 107 D'Agnano I, D'Angelo C, Savarese A et al. DNA ploidy, proliferative index, and epidermal growth factor receptor: expression and prognosis in patients with gastric cancers. Lab. Invest. 1995; 72; 432–438. 108 Esteban F, De Vega DS, Garcia R et al. DNA content by flow cytometry in gastric carcinoma: pathology, ploidy and prognosis. Hepatogastroenterology 1999; 46; 2039–2043. 109 Korenaga D, Okamura T, Saito A, Baba H, Sugimachi K. DNA ploidy is closely linked to tumor invasion, lymph node metastasis, and prognosis in clinical gastric cancer. Cancer 1988; 62; 309–314. 110 Yonemura Y, Ooyama S, Sugiyama K et al. Retrospective analysis of the prognostic significance of DNA ploidy patterns and S-phase fraction in gastric carcinoma. Cancer Res. 1990; 50; 509–514. 111 Kimura H, Yonemura Y. Flow cytometric analysis of nuclear DNA content in advanced gastric cancer and its relationship with prognosis. Cancer 1991; 67; 2588–2593. 112 Haraguchi M, Watanabe A, Moriguchi S et al. DNA ploidy is a major prognostic factor in advanced gastric carcinoma—univariate and multivariate analysis. Surgery 1991; 110; 814–819. 113 Yonemura Y, Ohoyama S, Kimura H et al. Independent clinical and flow cytometric prognostic factors for the survival of patients with stage I gastric cancer. Surg. Today 1992; 22; 416–420. 114 Rugge M, Sonego F, Panozzo M et al. Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis. Cancer 1994; 73; 1127–1133. 115 Yonemura Y, Fonseca L, Tsugawa K et al. Prediction of lymph node metastasis and prognosis from the assay of the expression of proliferation cell nuclear antigen and DNA ploidy in gastric cancer. Oncology 1994; 51; 251–257. 116 Flyger HL, Christensen IJ, Thorup J, Hakansson TU, Norgaard T. DNA aneuploidy in gastric carcinoma. Flow cytometric data related to survival, location, and histopathological findings. Scand. J. Gastroenterol. 1995; 3; 258–264. 117 Sakusabe M, Kodama M, Sato Y, Kikuchi T, Koyama K. Clinical significance of DNA ploidy pattern in stage III gastric cancer. World J. Surg. 1996; 20; 27–31. 118 Victorzon M, Roberts P, Haglund C, Von Boguslawsky K, Nordling S. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology 1996; 53; 182–191. 119 Santoro E, Carboni M, Catarci M et al. DNA ploidy, proliferative index and EDF-R status in 130 cases of resected gastric cancer—a multivariate analysis. Hepatogastroenterology 1997; 44; 826–837. 120 Setala LP, Nordling S, Kosma VM et al. Comparison of DNA ploidy and S-phase fraction with prognostic factors in gastric cancer. Anal. Quant. Cytol. Histol. 1997; 19; 524–532. 121 Abad M, Ciudad J, Rincon M et al. DNA aneuploidy by flow cytometry is an independent prognostic factor in gastric cancer. Anal. Cell. Pathol. 1998; 16; 223–231. 122 Russo A, Bazan V, Migliavacca M et al. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin. Cancer Res. 2000; 6; 178–184. 123 Danesi DT, Spanò M, Fabiano A et al. Flow cytometric DNA ploidy, p53, PCNA, and c-erbB-2 protein expression as predictors of survival in surgically resected gastric cancer patients. Cytometry 2000; 42; 27–34. 124 Russo A, Bazan V, Migliavacca M et al. DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma. Cancer 2001; 92; 294–302. 125 Sasaki K, Takahashi M, Hashimoti T, Kawachino K. Flow cytometric DNA measurement of gastric cancers. Clinicopathological implication of DNA ploidy. Pathol. Res. Pract. 1989; 184; 561–566. 126 Filipe M, Rosa J, Sandey A, Imrie P, Ormerod M, Morris R. Is DNA ploidy and proliferative activity of prognostic value in advanced gastric carcinoma? Hum. Pathol. 1991; 22; 373–378. 127 Bottger TC, Gabbert HE, Stockle TC et al. DNA image cytometry in stomach carcinoma. Its relation to histomorphologic parameters and its influence on prognosis. Cancer 1992; 70; 1819–1824. 128 Candel A, Green L, Castelli M, Abraham K, Aranha G, Gattuso P. Flow cytometry as a prognostic predictor in gastric linitis plastica. J. Surg. Oncol. 1994; 56; 233–235. 129 Omejc M, Repse S, Bracko M. DNA flow cytometry in gastric carcinoma: implication in patients with potentially curative resection. J. Surg. Oncol. 1997; 65; 237–241. 130 Lee KH, Lee JS, Lee JH et al. Prognostic value of DNA flow cytometry in stomach cancer: a 5-year prospective study. Br. J. Cancer 1999; 79; 1727–1735. 131 Kim JY, Cho HJ. DNA ploidy patterns in gastric adenocarcinoma. J. Korean Med. Sci. 2000; 15; 159–166. 132 Lee JH, Noh SH, Lee KY, Choi SH, Min JS. DNA ploidy patterns in advanced gastric carcinoma: is it a clinically applicable prognosticator? Hepatogastroenterology 2001; 48; 1793–1796. 133 Fujimaki E, Sasaki K, Nakano O et al. DNA ploidy heterogeneity in early and advanced gastric cancer. Cytometry 1996; 26; 131–136. 134 Stratmann H, Decker D, Hirner A, Bollmann R. Clinical importance and prognostic value of the image-DNA-cytometry for patients with gastric cancer. General Diagn. Pathol. 1996; 142; 97–100. 135 Lee KH, Lee JS, Suh C et al. DNA flow cytometry of stomach cancer. Prospective correlation with clinicopathological findings. Cancer 1993; 72; 1819–1826. 136 Lee KH, Lee JH, Cho JK et al. A prospective correlation of Lauren's histological classification of stomach cancer with clinicopathological findings including DNA flow cytometry. Pathol. Res. Pract. 2001; 197; 223–229. 137 Tsushimi T, Noshima S, Oga A, Esato K, Sasaki K. DNA amplification and chromosomal translocations are accompanied by chromosomal ins" @default.
• W2090192471 created "2016-06-24" @default.
• W2090192471 creator A5019453132 @default.
• W2090192471 creator A5038254746 @default.
• W2090192471 creator A5056121788 @default.
• W2090192471 date "2004-10-01" @default.
• W2090192471 modified "2023-10-16" @default.
• W2090192471 title "Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours?" @default.
• W2090192471 cites W151361642 @default.
• W2090192471 cites W1524908669 @default.
• W2090192471 cites W1541710158 @default.
• W2090192471 cites W1597072445 @default.
• W2090192471 cites W16051459 @default.
• W2090192471 cites W1618742753 @default.
• W2090192471 cites W1673808677 @default.
• W2090192471 cites W1694820831 @default.
• W2090192471 cites W1763504554 @default.
• W2090192471 cites W1777021921 @default.
• W2090192471 cites W1824572340 @default.
• W2090192471 cites W1900804936 @default.
• W2090192471 cites W1942180523 @default.
• W2090192471 cites W1963543531 @default.
• W2090192471 cites W1963627495 @default.
• W2090192471 cites W1964084689 @default.
• W2090192471 cites W1964531143 @default.
• W2090192471 cites W1964560778 @default.
• W2090192471 cites W1964582074 @default.
• W2090192471 cites W1964715298 @default.
• W2090192471 cites W1965537030 @default.
• W2090192471 cites W1966283226 @default.
• W2090192471 cites W1967126339 @default.
• W2090192471 cites W1967158462 @default.
• W2090192471 cites W1968305204 @default.
• W2090192471 cites W1969875009 @default.
• W2090192471 cites W1972147848 @default.
• W2090192471 cites W1972354502 @default.
• W2090192471 cites W1972523593 @default.
• W2090192471 cites W1972955523 @default.
• W2090192471 cites W1974285181 @default.
• W2090192471 cites W1974532738 @default.
• W2090192471 cites W1975053990 @default.
• W2090192471 cites W1975400400 @default.
• W2090192471 cites W1976813249 @default.
• W2090192471 cites W1977045267 @default.
• W2090192471 cites W1978520892 @default.
• W2090192471 cites W1979527413 @default.
• W2090192471 cites W1979969613 @default.
• W2090192471 cites W1980645806 @default.
• W2090192471 cites W1981722880 @default.
• W2090192471 cites W1982034092 @default.
• W2090192471 cites W1982121270 @default.
• W2090192471 cites W1986000793 @default.
• W2090192471 cites W1986229235 @default.
• W2090192471 cites W1986971238 @default.
• W2090192471 cites W1987727152 @default.
• W2090192471 cites W1987795062 @default.
• W2090192471 cites W1988521138 @default.
• W2090192471 cites W1989372056 @default.
• W2090192471 cites W1989819833 @default.
• W2090192471 cites W1989980745 @default.
• W2090192471 cites W1990495945 @default.
• W2090192471 cites W1991904568 @default.
• W2090192471 cites W1992868345 @default.
• W2090192471 cites W1993994790 @default.
• W2090192471 cites W1994639185 @default.
• W2090192471 cites W1995221307 @default.
• W2090192471 cites W1995304205 @default.
• W2090192471 cites W1995971703 @default.
• W2090192471 cites W1996185728 @default.
• W2090192471 cites W1997659398 @default.
• W2090192471 cites W1998385524 @default.
• W2090192471 cites W2002821991 @default.
• W2090192471 cites W2002978702 @default.
• W2090192471 cites W2005004596 @default.
• W2090192471 cites W2006253154 @default.
• W2090192471 cites W2007321429 @default.
• W2090192471 cites W2009846825 @default.
• W2090192471 cites W2010836872 @default.
• W2090192471 cites W2011061156 @default.
• W2090192471 cites W2012525194 @default.
• W2090192471 cites W2012585530 @default.
• W2090192471 cites W2012876773 @default.
• W2090192471 cites W2013340161 @default.
• W2090192471 cites W2014373328 @default.
• W2090192471 cites W2015131023 @default.
• W2090192471 cites W2017254507 @default.
• W2090192471 cites W2017723256 @default.
• W2090192471 cites W2018593330 @default.
• W2090192471 cites W2018984859 @default.
• W2090192471 cites W2019344577 @default.
• W2090192471 cites W2020375038 @default.
• W2090192471 cites W2020638848 @default.
• W2090192471 cites W2022349084 @default.
• W2090192471 cites W2024090397 @default.
• W2090192471 cites W2025142759 @default.
• W2090192471 cites W2025283845 @default.
• W2090192471 cites W2025343608 @default.
• W2090192471 cites W2025539276 @default.

• next